en · de · es · fr · pt
ipamorelin-notes.peptides6608.com › Data › Background And Structural Identity — Evidence Review

Background And Structural Identity — Evidence Review

By Editorial Desk · published 2026-01-19 · last reviewed 2026-02-19 · Data

growth hormone secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.

Storage Stability and Analytical Verification

Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.

Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Pentapeptide with C-terminal amide
Average massApproximately 711.9 DaValue derived from the formula
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
SolubilitySoluble in water and aqueous acetonitrileDissolution aided by acidic diluents
Common synonymsIpamorelin; NNC 26-0161Code name used in early reports

Ipamorelin Background and Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.

Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.

Related pages on this site

Handling, Storage and Analytical Verification

Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.

Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.

Ipamorelin Background and Receptor Selectivity

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Background from the literature

A polyhistidine-tag, best known by the trademarked name His-tag, is an amino acid motif in proteins that typically consists of at least six histidine (His) residues, often at the N- or C-terminus of the protein. It is also known as a hexa histidine-tag, 6xHis-tag, or His6 tag. The tag was invented by Roche, although the use of histidines and its vectors are distributed by Qiagen. Various purification kits for histidine-tagged proteins are commercially available from multiple companies. The total number of histidine residues may vary in the tag from as low as two, to as high as 10 or more His residues. N- or C-terminal His-tags may also be followed or preceded, respectively, by a suitable amino acid sequence that facilitates removal of the polyhistidine-tag using endopeptidases. This extra sequence is not necessary if exopeptidases are used to remove N-terminal His-tags (e.g., Qiagen TAGZyme). Furthermore, exopeptidase cleavage may solve the unspecific cleavage observed when using endoprotease-based tag removal. Polyhistidine-tags are often used for affinity purification of genetically modified proteins.

Biosynthesis of a particular hormone in a particular tissue. Storage and secretion of the hormone. Transport of the hormone to the target cell(s). Recognition of the hormone by an associated cell membrane or intracellular receptor protein. Relay and amplification of the received hormonal signal via a signal transduction process: This then leads to a cellular response. The reaction of the target cells may then be recognized by the original hormone-producing cells, leading to a downregulation in hormone production. This is an example of a homeostatic negative feedback loop. Breakdown of the hormone. Exocytosis and other methods of membrane transport are used to secrete hormones when the endocrine glands are signaled. The hierarchical model is an oversimplification of the hormonal signaling process. Cellular recipients of a particular hormonal signal may be one of several cell types that reside within a number of different tissues, as is the case for insulin, which triggers a diverse range of systemic physiological effects. Different tissue types may also respond differently to the same hormonal signal.

=== Europe === The U.S. market is being eclipsed by booming demand for cocaine in Europe, where users now pay twice the going U.S. rate. In 2008, U.S. Attorney General Michael Mukasey announced that an international drug interdiction operation, Project Reckoning, involving law enforcement in the United States, Italy, Canada, Mexico and Guatemala had netted more than 500 organized crime members involved in the cocaine trade. The announcement highlighted the Italian-Mexican cocaine connection. Concerns about European security and the trafficking of drugs through the European continent have grown in recent years, and, in December 2022, Europol and the DEA released a joint report on the situation involving Mexican drug trafficking through the EU. In December 2011, the government of Spain remarked that Mexican cartels had multiplied their operations in that country, becoming the main entry point of cocaine into Europe. In 2012, it was reported that Mexican cartels had joined forces with the Sicilian Mafia, when Italian officials unearthed information that Palermo's black market, along with other Italian ports, was used by Mexico's drug cartels as a conduit to bring drugs to the European market, in which they had been trafficking drugs, particularly cocaine, throughout the Atlantic Ocean for over ten years to Europe.

Sources: en.wikipedia.org

Reference notes

Recent research shows promising results in mortality and morbidity reductions when a state integrates drug monitoring programs with health information technologies and shares data through a centralized platform. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act was introduced by the US House of Representatives on June 22, 2018, and was advanced on June 22, 2018. The bill includes Medicare and Medicaid reform in order to improve treatment, recovery, and prevention efforts while also strengthening the fight against synthetic drugs like fentanyl. In September 2018, the US Senate approved the SUPPORT for Patients and Communities Act (H.R. 6). The committee reached a final agreement on terms of the bill on September 25, 2018. The final agreement included provisions from multiple other acts, such as The Opioid Crisis Response Act of 2018, The Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, and the Synthetics Trafficking and Overdose Prevention (STOP) Act of 2018. The House and The Senate passed the final draft on September 28 and October 3, respectively. President Donald Trump signed the package into law on October 28, 2018. In July 2019, English multinational consumer goods corporation Reckitt Benckiser, parent of US pharmaceutical company Indivior, agreed to pay $1.4 billion to the U.S.

== History == In 1908, what appears to be the first case of Urbach–Wiethe disease was reported by Friedrich Siebenmann, a professor of otolaryngology in Basel, Switzerland. In 1925, Friedrich Miescher, a Swiss dermatologist, reported on three similar patients. An official report of Urbach–Wiethe disease was first described in 1929 by a Viennese dermatologist and otorhinolaryngologist, Urbach and Wiethe. Its original name of 'lipoidosis cutis et mucosae' was changed to 'lipoid proteinosis cutis et mucosae' due to Urbach's belief that the condition was due to abnormal lipid and protein deposits within the tissues. Some have debated as to whether or not the disease is actually a form of mucopolysaccharidosis, amyloidosis, or even porphyria. The discovery of the Urbach–Wiethe disease causing mutation to the ECM1 gene has now provided a definitive way to differentiate Urbach–Wiethe disease from these other conditions. A woman with Urbach–Wiethe disease, S.M., was a woman unable to feel fear. She has been extensively studied, which helped determine the function of the amygdala.

Fish is a highly perishable product: the "fishy" smell of dead fish is due to the breakdown of amino acids into biogenic amines and ammonia. Live food fish are often transported in tanks at high expense for an international market that prefers its seafood killed immediately before it is cooked. Delivery of live fish without water is also being explored. While some seafood restaurants keep live fish in aquaria for display purposes or cultural beliefs, the majority of live fish are kept for dining customers. The live food fish trade in Hong Kong, for example, is estimated to have driven imports of live food fish to more than 15,000 tonnes in 2000. Worldwide sales that year were estimated at US$400 million, according to the World Resources Institute. If the cool chain has not been adhered to correctly, food products generally decay and become harmful before the validity date printed on the package. As the potential harm for a consumer when eating rotten fish is much larger than for example with dairy products, the U.S. Food and Drug Administration (FDA) has introduced regulation in the USA requiring the use of a time temperature indicator on certain fresh chilled seafood products. Because fresh fish is highly perishable, it must be eaten promptly or discarded; it can be kept for only a short time. In many countries, fresh fish are filleted and displayed for sale on a bed of crushed ice or refrigerated. Fresh fish is most commonly found near bodies of water, but the advent of refrigerated train and truck transportation has made fresh fish more widely available inland.

Sources: en.wikipedia.org

Reference notes

The genetic and nongenetic targets of the receptors differ between homo and heterodimers. Ligation of these receptors allows them to translocate to the nucleus and act as transcription factors either by binding estrogen response elements (ERE) on DNA or binding DNA together with other transcriptional factors e.g. Nf-kB or AP-1, both of which result in RNA polymerase recruitment and further chromatin remodelation. A non-transcriptional response to oestrogen stimulation was also documented (termed membrane-initiated steroid signalling, MISS). This pathway stimulates the ERK and PI3K/AKT pathways, which are known to increase cellular proliferation and affect chromatin remodelation.

=== Subsequent strikes associated with Venezuela === On 15 September, the US struck a boat allegedly transporting drugs from Venezuela during the morning hours, killing three people aboard the vessel. Following the attack, Trump wrote on social media in all capital letters: "Be warned—If you are transporting drugs that can kill Americans, we are hunting you!" Anonymous sources for The Guardian said leadership for the strike was provided by Stephen Miller, newly empowered via the Homeland Security Council. White House officials learned about the strike hours before it happened. Trump told reporters on 16 September that the US military had sunk a third boat in the Caribbean, without providing any other detail. Weeks later, Colombian President Gustavo Petro stated that one of the strikes may have killed a Colombian, and two unnamed US officials stated that there were Colombians on at least one of the boats. The White House responded that these assertions were baseless. On 18 October, Petro specified that he was referring to the 16 September strike announced by Trump; other sources said Petro was referring to the 15 September strike. On 3 October, a strike on a vessel near the coast of Venezuela killed four people. Hegseth wrote that the vessel was transporting substantial amounts of narcotics and at the time was heading towards the United States, adding that the vessel was operating on a known narco-trafficking transit route. On 14 October, six more people were killed in a strike on a vessel near the coast of Venezuela.

== Medicines == Treatments based on monoclonal antibodies have been produced related to CGRP or CGRP receptors. They have been shown to be effective in patients who experience migraine headaches, both with and without aura, and both episodic and chronic cluster headache. These are the first class of preventive medications originally designed and approved for people with migraine. Due to the nature of the monoclonal antibodies, they must be administered parenterally, preferably by injection. The first CGRP related medication approved by the FDA is called erenumab (trade name Aimovig), produced by pharmaceutical company Amgen and Novartis. It interacts with the CGRP receptor. It is injected once monthly with a dose of 70 or 140 mg. Few adverse effects were reported (most related to injection site reactions) and patients had a significant reduction in migraines. The second approved by the FDA is fremanezumab (trade name Ajovy), produced by the Teva Pharmaceuticals company. It interacts with the CGRP protein, whose expression is related to migraine attacks. It may be administered monthly or every three months, giving options for users. Trials have shown a reduction of greater than 50% of migraine days for those who responded. There were few significant side effects during trials, most related to injection site reactions. The third CGRP medication approved by the FDA is galcanezumab (trade name Emgality), produced by the Eli Lilly and Company. It interacts with the CGRP protein, whose expression is related to migraine attacks.

=== Alter ego === During her time on The Only Way Is Essex, Collins earned a reputation for being a diva. Her alter-ego was first created during the show's third series when her co-star Sam Faiers referred to Collins using her initials "The GC". Collins describes her alter-ego as an "intervention" and says she and The GC are "very different people". Speaking in 2020, she said "Although I'm Gemma Collins, I've got my brand the GC. Gemma Collins is a homely girl who loves watering hanging baskets. The GC, which is my brand, is basically a character that's over the top that people either love her or hate her, but on the back of her I've managed to launch perfumes and lipsticks." Collins embraces the term "diva" and says the word "empowers her". Her influences include Marilyn Monroe, Madonna, Beyoncé, Mariah Carey and Dolly Parton.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.

Has ipamorelin been approved for clinical use?

It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.

Why is selectivity emphasised in the literature?

Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.

How should lyophilized peptide be stored?

Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.

Network